Skip to main content
Nykode Therapeutics ASA logo

Nykode Therapeutics ASA — Investor Relations & Filings

Ticker · NYKD ISIN · NO0010714785 LEI · 254900UKQHWYZJD22017 OL Manufacturing
Open in API
Filings indexed 493 across all filing types
Latest filing 2024-05-07 Report Publication Anno…
Country NO Norway
Listing OL NYKD

About Nykode Therapeutics ASA

https://nykode.com/

Nykode Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company's core is its proprietary Vaccibody™ technology, a modular platform designed to create targeted vaccines. This technology works by linking antigens to a targeting unit, which delivers them directly to antigen-presenting cells. This mechanism is engineered to induce rapid, potent, and long-lasting T-cell and antibody immune responses. Nykode's development pipeline is focused on generating therapeutics for a range of diseases, with a primary emphasis on oncology and infectious diseases.

Recent filings

Filing Released Lang Actions
Nykode Therapeutics – invitation to Q1 2024 financial results presentation
Report Publication Announcement Classification · 99% confidence The document is a short announcement (3567 characters) stating that Nykode Therapeutics will release its first quarter 2024 financial results on May 14, 2024, and will host a subsequent webcast presentation. It explicitly mentions that the financial report and webcast can be accessed on the company's website. According to Rule #2 (The 'MENU VS MEAL' Rule), a short document announcing the publication of a report, rather than being the report itself, should be classified as a Report Publication Announcement (RPA). It is not the full Earnings Release (ER) or Interim Report (IR), but the notice about them.
2024-05-07 English
Nykode Therapeutics – invitation to Q1 2024 financial results presentation
Report Publication Announcement Classification · 99% confidence The document is an announcement dated May 7, 2024, stating that Nykode Therapeutics will release its 'first quarter 2024 financial results' on May 14, 2024, and will host a subsequent webcast presentation. It explicitly mentions that the 'financial report' will be accessible on the website. Since the document itself is an invitation/announcement about the upcoming release of the financial report (Q1 2024 results) and the associated presentation/call, and it is very short (3333 chars), it fits the definition of a Report Publication Announcement (RPA) rather than the comprehensive Interim Report (IR) or Earnings Release (ER) itself. It is announcing the publication of the results.
2024-05-07 English
Nykode Therapeutics ASA - Notice of Annual General Meeting
AGM Information Classification · 100% confidence The document is explicitly titled "INNKALLING TIL ORDINÆR GENERALFORSAMLING I NYKODE THERAPEUTICS ASA" (NOTICE OF ANNUAL GENERAL MEETING IN NYKODE THERAPEUTICS ASA). The agenda items cover standard AGM topics such as approval of the annual report, remuneration guidelines, election of the board, and authorization for share issuance, which are all typical components of a notice for an Annual General Meeting. This directly corresponds to the AGM-R (AGM Information) filing type.
2024-04-25 Norwegian
Nykode Therapeutics ASA - Notice of Annual General Meeting
AGM Information Classification · 100% confidence The document is explicitly titled "INNKALLING TIL ORDINÆR GENERALFORSAMLING I NYKODE THERAPEUTICS ASA" (NOTICE OF ANNUAL GENERAL MEETING IN NYKODE THERAPEUTICS ASA). The agenda items cover standard AGM topics such as approval of the annual report, remuneration guidelines, election of the board, and authorization for share issuance, which are all typical components of a notice for an Annual General Meeting. This directly corresponds to the definition for AGM Information (AGM-R). Although it mentions the Annual Report (2023), the document itself is the notice calling the meeting, not the report itself.
2024-04-25 Norwegian
Nykode Therapeutics ASA - Notice of Annual General Meeting
AGM Information Classification · 99% confidence The document is explicitly titled 'Nykode Therapeutics ASA - Notice of Annual General Meeting' and details the date, time, and location for the AGM to be held on May 16, 2024. This directly corresponds to the definition of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting. Although it is a 'Notice', the content is centered around the meeting itself, making AGM-R the most precise fit over a general RPA or RNS.
2024-04-25 English
Nykode Therapeutics Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer
Regulatory Filings Classification · 99% confidence The document is a formal announcement titled "Company Announcement" from Nykode Therapeutics ASA, dated April 19, 2024. It details the initiation of a Phase 2 clinical trial (VB-C-04) for their drug candidate VB10.16. This type of announcement, which communicates significant operational or clinical development news (like trial initiation, results, or partnerships) but is not a full financial report (like 10-K or IR) or a transcript, typically falls under general regulatory announcements or investor relations material. Since it is a press release announcing a specific corporate event (clinical trial initiation) and not a standardized SEC filing like 10-K, DEF 14A, or a specific financial report (ER, IR), it best fits the category for general regulatory/corporate news. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for significant, non-standardized corporate news releases that are not explicitly defined elsewhere. It is not an Earnings Release (ER), Interim Report (IR), or a presentation (IP).
2024-04-19 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.